Impact of Availability of Computer-Aided Detection Devices on Adenoma Detection During Colonoscopy: A Cluster Randomized Study.

GastroenterologyJun 5, 2026 (epub)
Clinical ResearchGastroenterology

Jason A Dominitz, Andrew J Gawron, Grace B McKee et al.

✦ AI-curated · Sources linked

In 30 seconds

This pragmatic, multicentre cluster-randomised quality improvement study assessed whether making computer-aided detection (CADe) devices available affected adenoma detection during colonoscopy at Veterans Health Administration facilities. Across 42 CADe and 97 control facilities, adenoma detection rate (ADR) rose from 50.7% to 54.9% at CADe sites, an absolute increase of 4.2 percentage points (95% CI, 3.48 to 4.74 percentage points); at control sites, ADR fell from 51.8% to 51.1%. In adjusted analysis, CADe availability was associated with higher odds of adenoma detection (odds ratio, 1.22; 95% CI, 1.15 to 1.28), without changes in other lesion detection or withdrawal time.

Key findings

  • ADR increased by 4.2 percentage points (95% CI, 3.48 to 4.74 percentage points), from 50.7% to 54.9%, at CADe sites.
  • At control sites, ADR decreased by 0.7 percentage points (95% CI, -1.16 to -0.28 percentage points), from 51.8% to 51.1%.
  • CADe availability was associated with higher odds of adenoma detection (odds ratio, 1.22; 95% CI, 1.15 to 1.28), but not with detection of other lesions or withdrawal-time changes.
  • Baseline endoscopist ADR quintile was not associated with the effect of CADe availability on ADR.

Why it matters

Adenoma detection is clinically relevant because endoscopists’ ADRs are inversely associated with patients’ risk of postcolonoscopy colorectal cancer death. This pragmatic study found improved adenoma detection when CADe was available in routine practice, addressing uncertainty from real-world studies that had generally not shown benefit. Whether the observed detection increase improves cancer outcomes remains unknown.

What to keep in mind

The study did not determine effects on cancer outcomes or potential endoscopist deskilling.

Source

Published in Gastroenterology. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.